Navigation Links
Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
Date:1/31/2008

TOKYO and WOODCLIFF LAKE, N.J., Feb. 1 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) and Eisai's U.S. subsidiary, Eisai Corporation of North America (Headquarters: New Jersey, the United States, Chairman & CEO: Hajime Shimizu), today announced a change in the schedule for submission to the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for E7389 (generic name: eribulin mesylate) for third-line treatment of advanced breast cancer in patients who were pretreated with anthracycline, taxane and capecitabine.

Eisai is committed to developing E7389 as a potential treatment for patients with advanced breast cancer. In a Phase II study of 299 patients with advanced breast cancer who had been heavily pretreated, the compound has shown promising anti-tumor activity, with a response rate of 14.1% by investigator evaluation and 9.3% by independent radiologist evaluation. It has also been shown in the Phase II study to be generally well-tolerated, with the most common Grades 3 and 4 drug-related adverse events being 54% in neutropenia and 14% in leucopenia. Grade 3 peripheral neuropathy occurred in 6% of study participants, and there were no Grade 4 events.

Eisai had planned to submit an NDA under Subpart H*, based on Phase II clinical trial data, to seek accelerated approval for E7389 as a third-line breast cancer treatment (monotherapy), but is precluded from doing so, because FDA approved another drug for this specific indication last October. Eisai remains committed to advancing two Phase III clinical trials for E7389, which are ongoing in the U.S. and in Europe, Study 301 for second-line and Study 305 for third-line breast cancer treatment. Eisai now plans to submit an NDA to FDA with data from these trials and Phase II clinical trial data in fiscal year 2009-2010. In addition, Eisai continues to evaluate E7389 as a potential treatment for a variety of other solid tumors, including non-small
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
2. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 AudioNotch is the internet's ... for the treatment of tinnitus. Patients listen to sound ... over a period of weeks to months, their tinnitus volume ... two forms: Notched Music and Notched White Noise. Now, AudioNotch ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of strategic ... business, and media events in the United States ... associate Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of service ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 iLab Solutions, the ... as the new Director of Product Strategy. In this role, ... as iLab sub-teams to guide in the development of iLab ... provides the maximum possible benefit to the scientific community by ...
(Date:1/14/2014)... Bellingham, Washington, USA, and Cardiff, UK (PRWEB) January 13, ... and photonics technology development leader with more than 20 ... international society for optics and photonics . Hainsey will ... “We are delighted to have Dr. Hainsey join SPIE ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... ... ... DuPont business Pioneer Hi-Bred and the American Farm Bureau Federation announced ... virtual education program. The donation from Pioneer Hi-Bred, paid over three years, will ...
... A new blood test that identifies changes in DNA ... through Quest Diagnostics Incorporated (NYSE: DGX ), the ... aid the detection of colorectal cancer, the third leading cause ... on DNA methylation of the Septin9 gene, a proprietary biomarker ...
... , , , , ... - Novel SNPs Modulate ECG Measurements Including Heart ... Into deCODE,AF(TM) Test , Scientists at deCODE genetics ... sequence of the human genome,(SNPs) that are involved in modulating the electrical ...
Cached Biology Technology:DuPont Pledges Support to My American Farm Initiative 2DuPont Pledges Support to My American Farm Initiative 3Quest Diagnostics Introduces Molecular Blood Test for Aiding Colorectal Cancer Detection 2Quest Diagnostics Introduces Molecular Blood Test for Aiding Colorectal Cancer Detection 3deCODE Finds Genetic Factors Impacting Key Clinical Measurements of Heart Activity and Disease Risk 2deCODE Finds Genetic Factors Impacting Key Clinical Measurements of Heart Activity and Disease Risk 3deCODE Finds Genetic Factors Impacting Key Clinical Measurements of Heart Activity and Disease Risk 4
(Date:4/17/2014)... one per eight hundred births, Down syndrome - or ... of intellectual disability. It results from a chromosomal abnormality ... of chromosome 21 (1% of the human genome). A ... the Department of Genetic Medicine and Development at the ... Nature , shed light on how the extra ...
(Date:4/17/2014)... produce hydrogen sulfide in order to properly multiply and ... the Center for Craniofacial Molecular Biology at the Herman ... Shi, principal investigator on the project, said the presence ... flow of calcium ions. The essential ions activate a ... the creation of new bone tissue, and keeps the ...
(Date:4/17/2014)... If a restaurant ... he can expect his premises to be trashed. Warnings like ... is enough to make restaurant owners pay up. Similarly, mafia-like ... in other birds, nests. If the host birds throw the ... destroying the entire nest. Consequently, it is beneficial for hosts ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... COLUMBIA, Mo. For 5,000 years, the Chinese have ... balance of positive and negative energies in the body. In ... the measures used to classify the overall physical status of ... developed computer software that combines the ancient practices and modern ...
... PARIS, May 25, 2012 Babolat, international ... interactive racquet, "Babolat Play & Connect," at the French ... innovation with nearly infinite potential. Welcome to the tennis ... of the first interactive racquet with organized demonstrations featuring ...
... Cold Spring Harbor, N.Y. In a study published ... Cold Spring Harbor Laboratory (CSHL) scientists describe the three-dimensional ... piece of RNA that "guides" the protein,s ability to ... in RNA interference (RNAi), a powerful cellular phenomenon that ...
Cached Biology News:Tongue analysis software uses ancient Chinese medicine to warn of disease 2"Babolat Play & Connect" - Worldwide Exclusive Event at the French Open 2"Babolat Play & Connect" - Worldwide Exclusive Event at the French Open 3"Babolat Play & Connect" - Worldwide Exclusive Event at the French Open 4CSHL researchers solve structure of human protein critical for silencing genes 2CSHL researchers solve structure of human protein critical for silencing genes 3
... solid. Increases the expression of glutathione peroxidase. ... 2 O. Unstable in aqueous solutions; reconstitute ... 3211-76-5, M.W. 196.1. References: Merck Index ... A.F. 1995. Biochem. J. 306, ...
... provide a thin film-like barrier when a circle is ... barrier creates the proper surface tension to hold an ... PAP Pen contains a special formulation which is ... removed, if desired, by xylene after the staining procedure ...
Mouse monoclonal antibody to QDPR - quinoid dihydropteridine reductase...
...
Biology Products: